Ustekinumab (Stelara®)


Indications for Prior Authorization:

  • Moderate to severe plaque psoriasis
  • Psoriatic arthritis
  • Crohn's Disease

Stelara is a preferred biologic agent for treatment of the following indications when all criteria below are met for specific indications:

  • Psoriatic Arthritis
  • Plaque Psoriasis
  • Crohn's Disease

Patients must meet the following criteria for the indications above:

Moderate to Severe Plaque Psoriasis

  • > 18 years of age, AND
  • Diagnosed and prescribed by a Dermatologist or Rheumatologist, AND
  • Baseline PASI score of 10 or more, psoriasis affecting 10% BSA or more, or psoriasis affecting palms, soles of feet, head/neck, or genitalia, AND
  • One of the following:
    • Inadequate response, intolerance or contraindication to PUVA or UVB treatment, OR,
    • UVB treatment, OR,
    • Has difficulty accessing PUVA or UVB. OR
  • One of the following:
    • Experienced inadequate response/intolerance to at least one of the following treatments: methotrexate, cyclosporine (Neoral®), acitretin (Soriatane®), OR
    • Contraindication to all of the treatments listed. (A trial of these agents is not applicable for females actively attempting to conceive).

Psoriatic Arthritis

  • Psoriatic arthritis diagnosed by a rheumatologist AND
  • Age > 18 years AND
  • Inadequate response, intolerance, or contraindication to one or more Disease Modifying anti-Rheumatic Drugs [(DMARDs) Auranofin (Ridaura®), Azathioprine (Imuran®), Cyclosporine (Neoral®), Methotrexate (Rheumatrex®), sulfasalazine (Azulfidine®), Leflunomide (Arava®)] OR has a medical reason why methotrexate, sulfasalazine, and leflunomide cannot be used.

Crohn’s disease

  • Failed or have a documented intolerance or contraindication to one agent from either of the following classes: oral corticosteroids or immunosuppressants (azathioprine, mercaptopurine, methotrexate, or cyclosporine), AND
  • Is not used in conjunction with another anti-TNF drug or interleukin-1 receptor antagonist

The drug is not covered for the following conditions:

  • Multiple Sclerosis
  • Any condition not listed in the indication section above


Moderate to Severe Plaque Psoriasis

  • ≤100 kg (220 pounds up to 45 mg initially and then four weeks later, followed by every 12 weeks
  • > 100 kg, up to 90 mg initially and then four weeks later, followed by every 12 weeks

Psoriatic Arthritis

  • Up to 45mg SC initially and 4 weeks later, followed by 45mg every 12 weeks
  • For co-existent moderate-to-severe plaque psoriasis in patients weighing >100kg (220lbs): up to 90mg SC initially and 4 weeks later, followed by 90mg every 12 weeks

Crohn's Disease

  • Induction: IV
    • 55 kg or less: 260 mg as single dose
    • More than 55 kg to 85 kg: 390 mg as single dose
    • Greater than 85 kg: 520 as single dose
  • Maintenance: SubQ: 90 mg every 8 weeks; begin maintenance dosing 8 weeks after the IV induction dose.


  • Initial approval six months to assess patient’s response
  • Renew for one year if patient has clinical response


  • Risk of Tuberculosis and Serious Infection
  • Patients should be evaluated for latent tuberculosis infection with a TB skin test
  • Treatment of latent tuberculosis infection should be initiated prior to therapy with golimumab
  • Do not administer live vaccines or attenuated vaccines concurrently with ustekinumab


Last review date: July 6, 2015

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar